Assessment of the risk of anti-VEGF treatment for chorioretinal disease among patients using mirabegron versus anticholinergics for overactive bladder syndrome

Continence · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles